ATAI Life Sciences N.V. - Common Shares (NQ: ATAI )
1.580
+0.070
(+4.64%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 24, 2025
Add to My Watchlist
Press Releases about ATAI Life Sciences N.V. - Common Shares
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
Topics
Cannabis
Exposures
Cannabis
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
September 22, 2022
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
September 22, 2022
Psychedelics Use Among Young Adults Reaches All-Time High
September 01, 2022
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
August 10, 2022
Topics
Supply Chain
Exposures
Supply Chain
Topics
Derivatives
Exposures
Derivatives
Topics
Law Enforcement
Exposures
Legal
Exposures
Product Safety
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
March 08, 2022
Topics
Economy
Exposures
Economy
Psychedelic Therapies Offer Hope for Mental Health
March 02, 2022
Psychedelic Therapies Offer Hope for Mental Health
March 02, 2022
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
January 19, 2022
A Recap of How Psychedelics Fared in 2021
January 07, 2022
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
November 17, 2021
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
September 30, 2021
Topics
Cannabis
Exposures
Cannabis
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Exposures
Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.